Background and Objectives：NF-κB transcription factors drive the expressions of many genes involved in inflammation and cell survival, which are both important in ischemia-reperfusion (IR) injury. IKK-β can mediate NF-κB activation through the phosphorylation of IκB; however, alternative pathways of activation exist. Materials and Methods：To test the role of IKK-β in cardiac IR injury, cardiac gene transfer of dominant negative IKK-β (dnIKK-β) was performed in rats 48 hr prior to IR. Results：Adeno-viral gene transfer was found to result in regional transgene expression encompassing ~60% of the ischemic area. Ad.dnIKK-β reduced the IR-induced NF-κB translocation and IκB-α degradation, and blocked induction of the NF-κB-dependent inflammatory chemokine, MCP-1, in the ischemic area compared to the Ad.EGFP.β-gal treated rats (p<0.05). Neutrophil infiltration in the ischemic area (as indicated by myeloperoxidase activity) was decreased by 33% in the Ad.dnIKK-β treated rats compared to the Ad.EGFP.β-gal treated rats (p<0.05). Ad.dnIKK-β also reduced IR-induced apoptosis, as reflected by the attenuated DNA laddering compared to rats injected with either buffer or Ad.EGFP.β-gal. The ischemic area was not affected by dnIKK-β expression. However, Ad.dnIKK-β reduced infarction(%MI) by 57% compared to the Ad.EGFP.β-gal treated rats (p<0.01). Conclusion：Thus, in vivo gene transfer of dnIKK-β prevents the IR-induced activation of NF-κB. In this setting, abrogation of pro-inflammatory signals appears more important than loss of NF-κB dependent survival factors, resulting in an overall reduction in apoptosis and infarct size. These data suggest that IKK-β may represent a valuable target for therapeutic intervention in IR injury. (Korean Circulation J 2005 ; 
Introduction
While the mainstay of current therapy in acute myocardial infarction(MI) is reperfusion, with many studies having demonstrated the clinical benefit of this approach, reperfusion is itself associated with myocardial damage; termed ischemiareperfusion(IR) injury. In animal models, cardiac IR injury is associated with early endothelial dysfunction, 1) increased adhesion molecule and cytokine expression, 2) 3) activation of the alternate complement pathway, 4) infiltration of circulating neutrophils, 5) release of oxygen free radicals, as well as other potentially toxic products, 4)6)7) and programmed cell death or apoptosis. 8)9) Understanding the basis of, and learning to minimize, the injury due to IR could maximize the benefits of reperfusion therapy in acute infarction.
The family of transcription factors, nuclear factor kappa B (NF-κB), is activated by diverse stimuli, including oxidative stress and inflammatory cytokines, which drive the expressions of many genes involved in inflammation and cell survival, both critical elements of IR injury. 1)10) In IR, NF-κB is activated early 11) and drives the expressions of cytokines and adhesion molecules, 2)3)12) which enhance local recruitment of inflammatory leukocytes that contribute to IR injury. However, NF-κB also drives the expression of survival factors that appear particularly important in cardiomyocytes. 13) Thus, while NF-κB inhibition might limit inflammation in IR, it could also potentiate cardiomyocyte apoptosis. Clinical manipulation of NF-κB is further complicated by the difficulty of targeting transcription factors through traditional pharmaceutical approaches. Conversely, a successful precedent exists for the clinical development of highly specific and effective kinase inhibitors, 14) and recent advances in our understanding of the mechanisms of NF-κB activation could lay the foundation for effective clinical manipulation of this pathway if appropriate molecular targets can be identified.
NF-κB generally exists as a dimer in the cytosol bound to one of three inhibitory, IκB, subunits. 15) A major mechanism of NF-κB activation is the serine phosphorylation and degradation of IκB, followed rapidly by translocation of NF-κB to the nucleus, where it activates transcription of specific promoter targets. In addition, some members of the NF-κB family, such as p65, can be regulated through direct phosphorylation of the transactivation domain(TAD), further enhancing gene transcription. 16) Two known kinases, IKK-α and IKK-β, can each phosphorylate IκB. 17) IKK-β is activated rapidly in the heart after IR. 10) Mice lacking IKK-β die as embryos, but their embryonic fibroblasts have defective NF-κB activation in response to cytokine stimulation. 18) IKK-α appears important for activation of one of the NF-κB family members(NF-κB2) and a subset of NF-κB dependent genes, particularly in B cells. 19) IKK-α is also important in skin development, but this function is independent of its kinase activity. 19) In addition, NF-κB activation can also be regulated by tyrosine phosphorylation of IκB, which leads to dissociation from p65 without IκB degradation. 20) The kinase responsible for this event has not been identified, but appears to be particularly important in NF-κB activation after hypoxia-reoxygenation. 20) Finally, recent data suggests reversible acetylation of p65 also modulates its association with IκB and transcriptional activity. 21) Thus, multiple mechanisms of NF-κB regulation exist, but their relative contribution to myocardial injury after IR is currently unknown.
To test the role of IKK-β in cardiac IR injury, the adenoviral gene transfer of a highly specific and effective dominant negative IKK-β mutant(K44A) was used and the effects on NF-κB activation, inflammation, apoptosis and cardiac injury examined. Our results suggest that targeting IKK-β may be an effective strategy to maximize the benefits derived from reperfusion therapy. 
Materials and Methods

Recombinant adenoviral vectors
Statistical analysis
All data were evaluated with a 2-tailed, unpaired Student's t test and expressed as the mean±SEM. p less than 0.05 were considered significant. All data shown represent at least three independent experiments.
Results
Adenoviral gene transfer in vivo
Direct injection of adenoviral vectors resulted in regional transgene expression in an area encompassing ~60% of the area subjected to ischemia (Fig. 1A) . Expression of the IKK-β protein was detected by immunoblotting only in Ad.dn-IKK-β injected myocardium (Fig. 1B) .
dnIKK-β blocks Iκ B-α phosphorylation and NF-κ B activation in cardiomyocytes
We examined whether dnIKK-β expression would block IκB phosphorylation and NF-κB activation in CM in vitro.
Cultured CM, transduced with Ad.EGFP.β-gal or Ad.dnIKK-β for 24 hours, were treated with recombinant rat TNF-α (50 ng/mL) for 10 to 30 minutes. After 10 minutes, TNF-α stimulation induced a significant increase in immunoreactive phospho-IκB-α and a decrease in total IκB-α in the Ad.
EGFP.β-gal infected cells( Fig. 2A) . In contrast, the IκB-α and phospho-IκB-α levels were only minimally affected by TNF-α treatment in the Ad.dnIKK-β infected cells( Fig. 2A) .
By 30 minutes, the rat TNF-α induced a significant increase in nuclear p65-NF-κB in the Ad.EGFP.β-gal infected cells (Fig. 2B) . This increase was significantly blocked by dnIKK-β expression, in a dose-dependent manner (Fig. 2B) . To determine whether transcription of NF-κB dependent genes was effectively blocked, we performed quantitative RT-PCR (QRT-PCR) on the RNA(100 ng) from the CM infected with Ad.dnIKK-β or Ad.EGFP.β-gal and stimulated with TNF-α(50 ng/mL, 3 hours). The amplified product was detected using SYBR1 fluorescence (Fig. 3A) . Importantly, a post-PCR melt curve analysis confirmed a single peak of amplified product of the appropriate T m , but there was no amplification in the absence of the template(data not shown).
After TNF-α treatment, a leftward shift was observed in the amplification curves, indicating a significant increase in the mRNA levels for each of the examined genes in the Ad.
EGFP.β-gal infected CM. This leftward shift was substantially inhibited in cells expressing dnIKK-β (shown for VCAM-1 in Fig. 3A) . Overall, dnIKK-β inhibited the induction of mRNA for VCAM-1 and ICAM-1(p<0.05, n=4 in each group) by 90±11 and 80±13%, respectively (Fig. 3B) .
dnIKK-β inhibits NF-κB activation in vivo
To investigate whether dnIKK-β expression could block NF-κB activation after IR in vivo, the myocardial nuclear and cytoplasmic proteins isolated from the ischemic areas of the hearts subjected to 30 minutes of ischemia and 30 minutes of reperfusion for IκB-α, as well as 30 minutes of ischemia and 24 hours of reperfusion for nuclear p65-NF-κB. The level of immunoreactive IκB-α decreased in the Ad.EGFP.β-gal treated hearts after IR. This decrease was blocked by dnIKK-β
Fig. 4. dnIKK-β inhibits NF-κB activation in vivo.
A: immunoblotting for IκB-α. IκB-α degradation was evident after 30 min of ischemia followed by 30 min of reperfusion in the Ad.EGFP.β-gal infected hearts compared with the non-ischemic hearts. In contrast, Ad.dnIKK-β treatment reduced IκB-α degradation after 30 min ischemia and 30 min reperfusion. B: immunoblotting for nuclear p65 in myocardium. Nuclear p65 increased after IR (30 min ischemia, 24 hr reperfusion) in the Ad.EGFP.β-gal and buffer treated myocardia. This increase was substantially inhibited in the Ad. dnIKK-β treated myocardium despite IR. All blots are representative of three independent experiments. C: confocal microscopy on Ad.dnIKK-β treated myocardium after IR. Confocal microscopy for GFP, which is co-expressed by Ad (Fig. 4A) . Similarly, a dramatic increase in nuclear p65 was evident in both the Ad.EGFP.β-gal and buffer treated rats by the immunoblotting after IR. In contrast, p65
nuclear translocation was substantially blocked in Ad.dnIKK-β treated rats (Fig. 4B) . In Ad.dnIKK-β injected myocardium, inhibition of p65 nuclear translocation was also evident on (Fig. 4C ).
We also examined the effect of dnIKK-β expression on the in vivo induction of the NF-κB-dependent inflammatory che- (Fig. 5) .
Ad.dnIKK-β reduces neutrophil infiltration after IR
NF-κB activation of inflammatory pathways is thought to and from hearts infected with either Ad.EGFP.β-gal or Ad.dnIKK-β and subjected to IR (30 min ischemia, 24 hr reperfusion). The MCP-1 concentration increased significantly in the ischemic regions (I) of the hearts treated with Ad.EGFP.β-gal compared to the non-ischemia regions (N) (p<0.05). In contrast, the MCP-1 concentration was significantly lower in the ischemic regions of the Ad.dnIKK-β treated hearts compared with the ischemic regions of the Ad.EGFP.β-gal infected hearts (p<0.05), but was not significantly different from the non-ischemic or normal myocardia (p=NS). Data shown are cumulative with four animals in each group. MCP-1: monocyte chemotactic protein-1. Fig. 6 . Effect of dnIKK-β on neutrophil infiltration after IR. A: myocardial MPO activity. As an index of neutrophil infiltration, the MPO activity was measured in ischemic and non-ischemic regions after IR (30 min ischemia, 24 hr reperfusion). The level of MPO increased significantly in the ischemic regions (I) from the Ad.EGFP.β-gal treated animals compared to the non-ischemic (N) or normal myocardia (p<0.01). In the Ad.dnIKK-β treated rats, this increase was significantly reduced compared with that in the Ad.EGFP.β-gal treated animals (p<0.05), but remained above the levels seen in the non-ischemic regions or control myocardia (p<0.05). B: the neutrophil counts were consistently and significantly lower in the dnIKK-β treated ischemic myocardium compared with the vehicle or control virus treated myocardia (p< 0.01, n=4 in each group). The data shown is cumulative, with four animals in each group. C: H & E staining of tissue from Ad.EGFP. β-gal and Ad.dnIKK-β treated myocardium after IR. Many neutrophils are evident infiltrating the ischemic tissue from the Ad. EGFP.β-gal treated myocardium (left panel), while fewer neutrophils are seen in the ischemic tissue from the Ad.dnIKK-β treated animals (right panel). Data shown are representative of four independent experiments. MPO: myeloperoxidase, GFPN: non-ischemic regions from the Ad.EGFP.β-gal treated rats, DNN: nonischemic regions from the Ad.dnIKK-β treated rats, GFPI: ischemic regions from the Ad.EGFP.β-gal treated rats, DNI: ischemic regions from the Ad.dnIKK-β treated rats, IR: ischemia-reperfusion, PMNs: polymorphonuclear neutrophils. hours of reperfusion in both Ad.EGFP.β-gal and Ad.dnIKK-β treated rats compared with normal hearts. However, the MPO activity in the ischemic area was decreased by 33% in the Ad.dnIKK-β treated compared with the Ad.EGFP.β-gal treated rats(90.7±7.8 vs. 134.9±17.9 OD/minute/mg protein, p<0.05, n=4 in each group) (Fig. 6A) . These data were consistent with the results of the histological evaluation of H & E-stained myocardium (Fig. 6C ). Neutrophils were rarely seen in the non-ischemic myocardium of either group, but were readily detected in ischemic myocardium. The neutrophil counts in the non-ischemic and ischemic myocardia were analyzed. For each heart, a midventricle cross section was taken, and 5 high power fields(HPFs, ×400) randomly chosen for counting. Polymorphonuclear neutrophils(PMNs) were identified on the basis of their unique appearance in hematoxylin and eosin-stained tissues. Neutrophil counts were consistently and significantly lower in the dnIKK-β treated ischemic myocardium compared with the vehicle or control virus treated myocardia(p<0.01, n=4 in each group) (Fig. 6B) . The number of neutrophils in the control virus treated myocardium was similar to that in the vehicle controls.
Infarct size and area at risk
To determine the impact of the observed reduction in inflammation on clinically relevant endpoints, the cumulative ischemic and infarcted areas were examined in hearts from animals treated with either Ad.dnIKK-β or Ad.EGFP.β-gal. vs. 43.5±14.5%, p<0.01, n=8 in each group) (Fig. 7) .
Apoptosis
Since apoptosis can contribute to myocardial injury in IR, 22) and CM require NF-κB-dependent survival factors in some settings, 13) the effect of dnIKK-β expression was examined on the DNA laddering, a biochemical hallmark of apoptosis. Left ventricular(LV) samples were divided into ischemic and nonischemic areas, as delineated by the fluorescent microsphere distribution. DNA were extracted from LV samples, and subjected to agarose gel electrophoresis. DNA laddering was not observed in the non-ischemic myocardium of animals treated with buffer alone, Ad.EGFP.β-gal or Ad.dnIKK-β(n=4 in Fig. 7 . Ad.dnIKK-β reduces infarction after IR. Representative micrograph (right panel) revealing the fluorescent microsphere distribution (top) and TTC staining (bottom) in rats subjected to IR after gene transfer with either Ad.EGFP.β-gal (Left) or Ad.dnIKK-β (Right). The bar graph shows cumulative data for AAR and %MI from Ad.EGFP.β-gal and Ad.dnIKK-β treated animals (n=8 in each group) after IR. There was no significant difference in the ischemia areas (AAR) between the groups. In contrast, infarction (%MI) was reduced by 57% in the Ad.dnIKK-β treated animals (p<0.01). MI: myocardial infarction, AAR: area-at-risk. Ad.dn-IKK-β each group). However, prominent DNA laddering was evident in the ischemic myocardium from the buffer and Ad.EGFP. β-gal treated rats. This laddering was markedly attenuated by dnIKK-β expression (Fig. 8) .
Discussion
The role of IKK-β was examined in an in vivo model of cardiac ischemia-reperfusion injury through adenoviral gene transfer of a dominant negative mutant. We found that gene transfer achieved local expression of the dnIKK-β in the ischemic region, inhibiting IκB-α degradation and p65 nuclear translocation. The expression of MCP-1, an NF-κB-dependent inflammatory mediator, was reduced, as was the neutrophil infiltration after IR. Overall, apoptosis was reduced in the ischemic regions of hearts injected with the Ad.dnIKK-β.
Although the ischemic "area-at-risk" did not differ between animals treated with Ad.EGFP.β-gal or Ad.dnIKK-β, the dnIKK-β expression dramatically protected hearts from injury, reducing the infarct size by 78%. These data establish an important role for IKK-β in the adult heart after IR in vivo, and suggest that a significant proportion of the myocardial damage sustained after IR can be prevented by specific inhibition of this kinase.
The IKK complex is composed of two catalytic subunits (IKK-α and IKK-β) and a regulatory subunit(IKK-γ).
IKK-α and IKK-β differ in their substrate specificities and have distinct functions. The interaction of IKK-γ with IKK-α and IKK-β is critical for the assembly of the IKK complex leading to NF-κB activation in response to a variety of different signals. 19) Our results are consistent with prior reports documenting the early activation of NF-κB and IKK-β in cardiac IR, 11)28) with the consequent expression of pro-inflammatory molecules 12) that are thought to mediate neutrophil recruitment. A previous study utilized oligonucleotide decoys to inhibit NF-κB in IR, which demonstrated a similarly dramatic reduction in cardiac injury. 29) However, the current work extends these studies by demonstrating the functional significance of a specific pathway of NF-κB activation in this setting. Thus, IKK-β signaling appears necessary for NF-κB activation in cardiac IR, suggesting any contribution by alternative pathways(tyrosine phosphorylation 20) ), IKK-α, 19) or acetylation 21) is likely to be minor in this setting. However, from a clinical perspective, these results also suggest that inhibitors of IKK-β might provide an important adjunctive therapy after cardiac reperfusion.
IKK-β may have significant advantages as a pharmacologic target compared with agents directly targeting IκB or NF-κB. Not only is there considerable experience with clinical development of specific kinase inhibitors, 14) but well-characterized compounds(e.g. salicylates) already exist that inhibit IKK-β, 30) which could provide a springboard for the development of future small molecule inhibitors. While it may be tempting to speculate that some of the benefits of aspirin after reperfusion therapy could derive from inhibition of IKK-β, both the pleiotropic effects of aspirin and the relatively low doses administered clinically in this setting suggest other mechanisms may be the primary contributors. Thus, it is possible that specific and effective inhibitors of IKK-β could be developed that might prove to be valuable additions to the current therapy for acute infarctions.
dnIKK-β substantially blocked NF-κB activation and CM expression of pro-inflammatory genes both in vitro and in vivo. Since MCP-1 is thought to act predominantly on mononuclear cells, it is unlikely to play a major role in acute IR injury, so was used here simply as an index. Interestingly, although NF-κB activation, MCP-1 expression and infarct size were dramatically reduced, the reduction in the MPO activity was less dramatic, but still significant. This apparent discrepancy may reflect a non-linear relationship between these various endpoints or the inadequacy of MPO as a reflection of both the neutrophil numbers and activation. Alternatively, it is possible that neutrophil-independent mediators of tissue injury are favorably modulated by dnIKK-β expression. Thus, it is likely that the inhibition of neutrophil infiltration contributed to the benefits observed, but may not be wholly responsible.
NF-κB has been reported to suppress apoptosis in ventricular myocytes in vitro, 13) but we were surprised to observe a reduction in apoptosis in vivo. Although previous work has suggested that most of the apoptotic cells after IR are cardiomyocytes, 22) it is possible that alterations in the number of apoptotic neutrophils contributed to this difference. Nevertheless, there was no evidence of increased apoptosis that could have resulted from NF-κB inhibition. Of note, the expression of dnIKK-β dramatically enhanced apoptosis in vitro in neonatal cardiomyocytes exposed to TNF-α(50 ng/ mL), which has also been reported for IκB-α expression 13) (data not shown). These results suggest that the reduced apoptosis and infarction observed in vivo after dnIKK-β expression was secondary to a reduction in NF-κB-dependent inflammatory mediators. In this in vivo setting, abrogation of 
